News
![If I Could Only Buy 1 Stock Right Now, This Would Be It: https://g.foolcdn.com/editorial/images/755811/23_11_20-a-medical-professional-filling-a-needle-from-a-bottle-of-medicine-_mf-dload-vaccine-needle-injection-doctor-1200x801-d21b45d.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMERlYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f5b053680518b09af313a3783769c046ef93c6d5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/23_11_20-a-medical-professional-filling-a-needle-from-a-bottle-of-medicine-_mf-dload-vaccine-needle-injection-doctor-1200x801-d21b45d.jpg?locale=us)
If I Could Only Buy 1 Stock Right Now, This Would Be It
Medtronic (NYSE: MDT) is a stock I bought and have added to several times. I'm not a healthcare-focused investor, but the stock's historically high 3.6% dividend yield and long history of annual
![Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant: https://g.foolcdn.com/editorial/images/755562/doctor-giving-a-patient-medication.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMUhkYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3979826a3d4e44da79e979d74baa4f65f34d9d7f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-giving-a-patient-medication.jpg?locale=us)
Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant
Weight-loss drugs present an enormous opportunity in the healthcare market. Wegovy and Mounjaro are some of the top-selling drugs available in that indication, and companies that make them -- Novo
![The Smartest Stocks to Buy With $20 Right Now and Hold Forever: https://g.foolcdn.com/editorial/images/755891/gettyimages-758286251.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMWZkYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8ec6efdd7efa9c1a0ef7d09e1389da5e3019bf69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-758286251.jpg?locale=us)
The Smartest Stocks to Buy With $20 Right Now and Hold Forever
You don't need a lot of money to get going in the market these days. The growing popularity of zero-commission trading means that even $20 is more than enough to buy a piece of a potentially
![AT&T Stock Is Still Dirt Cheap After Surging Nearly 20%: https://g.foolcdn.com/editorial/images/755725/telecom-worker-woman-industrials-5g-tech-9.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd3pkYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cc331f06564cbcbbad8128052fb5be4a2b0a3cfd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/telecom-worker-woman-industrials-5g-tech-9.jpg?locale=us)
AT&T Stock Is Still Dirt Cheap After Surging Nearly 20%
Shares of telecom giant AT&T (NYSE: T) have been stuck in a rut for much of 2023. Slowing subscriber growth, an uncertain economic outlook, mountains of debt, and fear that the company's free cash
![Why Medtronic Stock Trounced the Market on Tuesday: https://g.foolcdn.com/editorial/images/755874/patient-and-physician-smiling-during-a-visit.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNy9jYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0b545c0e5cbd57fd21b5c31ecf84a09d7fcf54b9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/patient-and-physician-smiling-during-a-visit.jpg?locale=us)
Why Medtronic Stock Trounced the Market on Tuesday
Medical-devices company Medtronic's (NYSE: MDT) stock was in good health on Tuesday. Following the company's release of its latest set of quarterly figures, investors traded it up by nearly 5%. That
![Medtronic (MDT) Q2 2024 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
Medtronic (MDT) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
Medtronic (NYSE: MDT)Q2 2024 Earnings CallNov 21, 2023, 8:00 a.m. ET
Ryan Weispfenning
Source Fool.com
EQS-Adhoc: Fresenius Medical Care AG & Co. KGaA: Favorable settlement agreement with U. S. government with positive earnings impact of approx. EUR 175 million – 2023 earnings outlook raised
![Is This Healthcare Stock's 10% Yield a Steal of a Deal or Too Good to Be True?: https://g.foolcdn.com/editorial/images/755561/a-rich-person-counting-money.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2JjYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--187e0daa018d21f33884e754ac0d333542419890/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-rich-person-counting-money.jpg?locale=us)
Is This Healthcare Stock's 10% Yield a Steal of a Deal or Too Good to Be True?
A dividend yield can tell you a lot about a payout. Not only does it tell you how much you could be collecting in dividend income, but it can give you an indication of investor sentiment, and
EQS-News: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
EQS-Adhoc: Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
![Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How.: https://g.foolcdn.com/editorial/images/755494/investor-talks-with-group-of-medical-professionals.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOXphYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ca4d99b4184e37a0e0603367e267d7cf4ab03cc3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-talks-with-group-of-medical-professionals.jpg?locale=us)
Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How.
Novo Nordisk's (NYSE: NVO) Ozempic is indicated to treat diabetes, and its wild success and household name is making a few cardiometabolic device companies rather nervous. With a powerful tool to
![Eyeing Bonds Because of High Interest Rates? Try These 2 Dividend Stocks Instead: https://g.foolcdn.com/editorial/images/755308/bitcoin-investments-checking-on-smartphone-computer.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN2JhYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cc0f2960b159a3d5a7e23b68e7f036f03b1951d7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/bitcoin-investments-checking-on-smartphone-computer.jpg?locale=us)
Eyeing Bonds Because of High Interest Rates? Try These 2 Dividend Stocks Instead
The Federal Reserve (Fed) is the central bank of the U.S., responsible for regulating banks, implementing monetary policy, and maintaining the financial system's stability. One aspect of the latter
EQS-News: Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) and (3) of the Regulation (EU) No 596/2014 and Art. 2 (2) and (3) of the Delegated Regulation (EU) 2016/1052
EQS-Adhoc: Bayer Aktiengesellschaft: OCEANIC-AF study stopped early due to lack of efficacy
![Here's Why I Like AT&T Stock: https://g.foolcdn.com/editorial/images/755586/person-talking-on-a-landline.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNS9hYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d34c25f96a74f01d5767ddcee6b8fc08d0ccc3d5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-talking-on-a-landline.jpg?locale=us)
Here's Why I Like AT&T Stock
Dividend stocks offer many potential benefits to investors. They can provide income, boost returns through dividend reinvestment plans, act as a hedge against inflation and economic downturns, and
![2 Stock Split Growth Stocks to Buy and Hold: https://g.foolcdn.com/editorial/images/755119/a-person-working-on-a-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNVRhYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b4d00fa1d1591a0e800b612e0f30907c54d0340b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-person-working-on-a-laptop.jpg?locale=us)
2 Stock Split Growth Stocks to Buy and Hold
Last year, tech giant Amazon (NASDAQ: AMZN) and medical device specialist DexCom (NASDAQ: DXCM) were among the several high-profile companies to conduct stock splits. This move attracted plenty of
![Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire?: https://g.foolcdn.com/editorial/images/755461/gettyimages-1135625573.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMTdhYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6d0845ce18fc6c05f3dc6c0951f474ad70f6332c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1135625573.jpg?locale=us)
Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire?
All eyes have been on CRISPR Therapeutics (NASDAQ: CRSP) in recent times because the biotech company has reached a key moment. CRISPR Therapeutics and partner Vertex Pharmaceuticals are awaiting
![Is Beam Therapeutics Stock a Buy Now?: https://g.foolcdn.com/editorial/images/755074/healthcare-worker-ipad-nurse-doctor-hospital.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeXJhYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9adc1f6c77931f4cd85649ce139532f59d3de1db/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/healthcare-worker-ipad-nurse-doctor-hospital.jpg?locale=us)
Is Beam Therapeutics Stock a Buy Now?
When it comes to gene-editing companies on the cutting edge, Beam Therapeutics (NASDAQ: BEAM) is keen to be one of the leaders. While it's a bit of a laggard in terms of its pipeline's maturity
![3 Monster Stocks in the Making: https://g.foolcdn.com/editorial/images/755403/dna-on-monitor-scientists.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeFhhYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--896e5d8f945212f496a17377de9c34834e94500b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dna-on-monitor-scientists.jpg?locale=us)
3 Monster Stocks in the Making
Most, if not all, of the market's current mega-cap stocks started out much smaller. Investors who spotted their potential early had opportunities to make fortunes over time.
Which smaller stocks
![You Don't Have to Pick a Winner in Biotech. Here's Why.: https://g.foolcdn.com/editorial/images/755345/gettyimages-research-team-smiles-in-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeFBhYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--bb3dca34e2f6fa62eea71fec2720ae85632022de/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-research-team-smiles-in-lab.jpg?locale=us)
You Don't Have to Pick a Winner in Biotech. Here's Why.
The biotech company that's able to deliver the next game-changing treatment might become tomorrow's winner -- and offer your portfolio a giant boost.
Problem is, it's not always easy to identify
![Why CRISPR Therapeutics Stock Is Jumping Again Today: https://g.foolcdn.com/editorial/images/755478/scientists-smiling-and-shaking-hands.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN0haYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c908a5c27729a0a6884648a0234c483d6c939988/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-smiling-and-shaking-hands.jpg?locale=us)
Why CRISPR Therapeutics Stock Is Jumping Again Today
Shares of CRISPR Therapeutics (NASDAQ: CRSP) were jumping 10.1% higher as of 10:58 a.m. ET on Friday. The solid move followed Thursday's gain of more than 8%.
There's a good reason for this
![Is DexCom the Next Big Growth Stock?: https://g.foolcdn.com/editorial/images/755210/investor-sitting-at-computer-with-pen.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNkhaYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dd6252ac5077982e8f2221cae3bf441dfa624be0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-sitting-at-computer-with-pen.jpg?locale=us)
Is DexCom the Next Big Growth Stock?
With shares of DexCom (NASDAQ: DXCM) falling 11% this year amid a steadily rising market, one might think that the medical device maker's growth potential is ebbing compared to its former glory. But
![AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock: https://g.foolcdn.com/editorial/images/755206/healthcare-lab-treatment-research-scientist.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNVBaYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1bded62f3ae874e1533a265356990ac87994fdea/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/healthcare-lab-treatment-research-scientist.jpg?locale=us)
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
U.K.-based AstraZeneca (NASDAQ: AZN) is now gearing up for the second time to develop a challenger to Novo Nordisk's (NYSE: NVO) Ozempic, its absurdly successful treatment for type 2 diabetes. If
![Could DexCom Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/754788/two-couples-on-a-yacht.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMVBZYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--eadc9e73a0b07e71bf58deda5502654a572e8b23/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-couples-on-a-yacht.jpg?locale=us)
Could DexCom Stock Help You Become a Millionaire?
Getting to $1 million is a great long-term goal for investors to target. Not only could that be a good nest egg to tap into during retirement, but you could also use that money to invest in dividend
![Is Vertex Pharmaceuticals Stock a Buy Now?: https://g.foolcdn.com/editorial/images/754701/physician-giving-a-high-five-to-a-young-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN2ZYYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a07339c152a874a05e316bd6687e94efbff98542/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-giving-a-high-five-to-a-young-patient.jpg?locale=us)
Is Vertex Pharmaceuticals Stock a Buy Now?
If past performance guaranteed future success, Vertex Pharmaceuticals (NASDAQ: VRTX) would be one of the best biotech stocks to invest in. The drugmaker has consistently outperformed the broader